Alpha-L-fucosidase as a putative prognostic biomarker in breast cancer

The Ukrainian Biochemical Journal Pub Date : 2024-06-14 DOI:10.15407/ubj96.03.057

Z. M. A. A. Hamodat, H. H. Abdulwahhab, A. R. M. T. Hamodat

{"title":"Alpha-L-fucosidase as a putative prognostic biomarker in breast cancer","authors":"Z. M. A. A. Hamodat, H. H. Abdulwahhab, A. R. M. T. Hamodat","doi":"10.15407/ubj96.03.057","DOIUrl":null,"url":null,"abstract":"Search for reliable biomarkers for predicting progression of breast cancer is essential in managing the disease. So, we are trying to provide new insights into the potential role of alpha-fucosidase (AFU) as a putative prognostic biomarker in breast cancer as compared to classic markers. The study included 56 women with breast cancer; 25 had early breast cancer, and the rest (31) had metastatic breast cancer. Thirty healthy women were considered a control group. Early breast cancer patients had a significantly increased (P ≤ 0.0001) AFU level compared with the control group. A non-significant difference in the De-ritis ratio appeared for early breast cancer compared with control. Metastatic breast cancer had a significantly (P ≤ 0.0001) increased AFU and De-ritis ratio compared with early breast cancer and the control group. A positive significant (P = 0.01) correlation exists between AFU level, age factor (r = 0.295), and the De-ritis ratio in breast cancer patients. We can conclude that it is possible to consider alpha-L-fucosidase (AFU) as a putative prognostic biomarker in breast cancer more potent than the ratio of De-Ritis. Moreover, the coincidence of elevated AFU and De-ritis levels in metastatic breast cancer gives us an idea of the stage of the disease. Keywords: alpha-L-fucosidase, early breast cancer, metastasis, the De-ritis ratio","PeriodicalId":508485,"journal":{"name":"The Ukrainian Biochemical Journal","volume":"1 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Ukrainian Biochemical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/ubj96.03.057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Search for reliable biomarkers for predicting progression of breast cancer is essential in managing the disease. So, we are trying to provide new insights into the potential role of alpha-fucosidase (AFU) as a putative prognostic biomarker in breast cancer as compared to classic markers. The study included 56 women with breast cancer; 25 had early breast cancer, and the rest (31) had metastatic breast cancer. Thirty healthy women were considered a control group. Early breast cancer patients had a significantly increased (P ≤ 0.0001) AFU level compared with the control group. A non-significant difference in the De-ritis ratio appeared for early breast cancer compared with control. Metastatic breast cancer had a significantly (P ≤ 0.0001) increased AFU and De-ritis ratio compared with early breast cancer and the control group. A positive significant (P = 0.01) correlation exists between AFU level, age factor (r = 0.295), and the De-ritis ratio in breast cancer patients. We can conclude that it is possible to consider alpha-L-fucosidase (AFU) as a putative prognostic biomarker in breast cancer more potent than the ratio of De-Ritis. Moreover, the coincidence of elevated AFU and De-ritis levels in metastatic breast cancer gives us an idea of the stage of the disease. Keywords: alpha-L-fucosidase, early breast cancer, metastasis, the De-ritis ratio

查看原文本刊更多论文

作为乳腺癌预后生物标记物的α-L-岩藻糖苷酶

寻找可靠的生物标志物来预测乳腺癌的进展对控制病情至关重要。因此，我们试图对α-岩藻糖苷酶（AFU）作为乳腺癌预后生物标志物的潜在作用提供新的见解。这项研究包括 56 名乳腺癌妇女，其中 25 人患有早期乳腺癌，其余 31 人患有转移性乳腺癌。30名健康妇女被视为对照组。与对照组相比，早期乳腺癌患者的 AFU 水平明显升高（P ≤ 0.0001）。与对照组相比，早期乳腺癌患者的去炎症比率无明显差异。与早期乳腺癌和对照组相比，转移性乳腺癌的 AFU 和 De-ritis 比率明显增加（P ≤ 0.0001）。乳腺癌患者的 AFU 水平、年龄因素（r = 0.295）和去炎症比率之间存在明显的正相关（P = 0.01）。我们可以得出结论，可以将α-L-岩藻糖苷酶（AFU）视为比去炎症比率更有效的乳腺癌预后生物标志物。此外，在转移性乳腺癌中，α-L-岩藻糖苷酶和去炎症水平的升高可以让我们了解疾病的阶段。关键词：α-L-岩藻糖苷酶、早期乳腺癌、转移、去炎比值

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Ukrainian Biochemical Journal

自引率

0.00%

发文量